Surrozen stops IBD program due to dose concerns and competition

Surrozen’s inflammatory bowel disease treatment is hitting the curb after the biotech had difficulty nailing a safe dose in healthy volunteers.

The company said Thursday that between the dosing challenges and the competitive marketplace, it was discontinuing further development of SZN-1326 for IBD—the only indication the asset was being developed for, according to Surrozen’s pipeline.